Research News on Targeted Therapies 108 Pages
In recent years, a number of exciting new treatments for breast cancer have become available. Many of these treatments are called targeted therapies because they target specific characteristics of cancer cells and don’t harm healthy, normal cells. New targeted therapies are emerging on a regular basis, and the results of clinical trials and studies of these new medications are encouraging.
When studies about targeted therapies are published, Breastcancer.org publishes articles about the results and offers practical information on how the findings may affect YOU and your lifestyle.
These articles are part of the Breastcancer.org Research News program. Our experts examine recent breast cancer research for exciting advances, important updates, and changes in how breast cancer is treated and diagnosed.
We present these studies in easy-to-understand language, explaining their importance and what impact the results might have for YOU.
If you'd like to be notified about upcoming Research News reports, as well as other important Breastcancer.org programs, including Ask-the-Expert Online Conferences, we encourage you to sign up for free email updates.
108 Pages for Research News on Targeted Therapies
- Large Review Study Confirms Herceptin’s Benefits
- Studies Evaluate Treatments Before Surgery for HER2-Positive Disease
- Afinitor Before Surgery Doesn’t Help Treat HER2-Negative Breast Cancer
- Adding Avastin Slows Growth of Metastatic, HER2-Positive Disease
- Heart Problems Caused by Herceptin May Be More Common Than Thought
- Experimental Omnitarg May Help Treat Metastatic, HER2-Positive Disease
- Afinitor Helps Slow Growth of Certain Advanced-Stage Breast Cancers
- FDA Removes Breast Cancer Indication from Avastin
- Experimental Vaccine May Help Treat Some Advanced-Stage Cancers
- Treating Early-Stage, HER2-Positive Disease with Herceptin and Chemo Combo with No Anthracycline Reduces Heart Risks
- Avastin Plus Taxol May Help Treat Metastatic, Triple-Negative Disease
- Adding Iniparib to Second, Third Chemo Regimen May Help Treat Metastatic, Triple-Negative Disease
- Nexavar Offers No Benefits in Treating Advanced-Stage Disease
- Chemo Plus Herceptin Can Put Metastatic, HER2-Positive Disease Into Remission
- Blue Shield of California Will No Longer Pay for Avastin to Treat Advanced-Stage Breast Cancer
- Afinitor Added to Aromasin Slows Advanced-Stage Breast Cancer Growth
- Tykerb Alone Doesn’t Work as Well as Herceptin Alone to Treat Early-Stage, HER2-Positive Disease
- Lapatinib Fails as Breast Cancer Monotherapy
- Older Women with Existing Heart Problems, Diabetes Have Higher Risk of Heart Function Problems with Herceptin
- National Comprehensive Cancer Network Continues Support of Avastin for Metastatic Breast Cancer
- Afinitor Study Stopped Early Because of Good Results
- Medicare Will Continue Paying for Avastin to Treat Metastatic Breast Cancer
- FDA Expert Panel Recommends Removing Breast Cancer Indication from Avastin
- Adding Tykerb to Herceptin and Chemo Improves Survival in Metastatic, HER2-Positive Disease
- Experimental Dovitinib Seems to Offer No Benefits for Metastatic, HER2-Negative Disease
- Iniparib Doesn’t Seem to Help Treat Metastatic, Triple-Negative Disease
- Nexavar May Help Treat Some Metastatic Breast Cancers
- Tykerb and Xeloda Can Help Treat Breast Cancer That’s Spread to the Brain
- New Medicines That Slow Cancer’s Growth Don’t Seem to Improve Survival
- Avastin Slows Growth of Metastatic Breast Cancer
- Herceptin After Surgery Reduces Recurrence Risk of HER2-Positive, Early-Stage Disease
- Avastin Not Recommended to Treat Breast Cancer by British Agency
- Experimental Iniparib Increases Survival Only Slightly in Metastatic Triple-Negative Disease
- Genentech Asks FDA for Full Hearing on Avastin
- Women Treated with Avastin Have Higher Risk of Congestive Heart Failure
- Experimental Iniparib May Help Treat Triple-Negative Disease
- FDA Recommends Removing Avastin’s Breast Cancer Indication
- Experimental Combo of Herceptin and Omnitarg Helps Treat Advanced-Stage HER2-Postitive Disease
- Real World Survival Stats for Avastin Mirror Clinical Results
- Experimental Iniparib Shows Promise in Treating Advanced-Stage Disease
- Researchers Recommend Having Port in Place for Week Before Starting Avastin
- Herceptin More Effective Than Tykerb When Given Before Surgery
- Herceptin and Tykerb Added to Chemo Before Surgery More Effective Than Adding Only One to Treat Early-Stage, HER2-Positive Disease
- Avastin Added to Chemo Before Surgery Offers No Benefit
- Herceptin-Tykerb-Chemo Combo Before Surgery May Help Treat Early-Stage HER2-Positive Disease
- Herceptin May Help Treat Small, Early-Stage HER2-Positive Breast Cancers
- Experimental Medicine May Help Treat Advanced-Stage Breast Cancer
- Herceptin Effectiveness Not Affected by Obesity
- Herceptin Works Well in Older Women Diagnosed with HER2-Positive, Metastatic Disease
- Experimental Iniparib Plus Chemo Can Help Treat Metastatic, Triple-Negative Disease
- Experimental T-DM1 May Help Treat Metastatic, HER2-Positive Disease
- Herceptin-Avastin-Taxotere Combo Can Help Treat Metastatic HER2-Positive Breast Cancer
- FDA Turns Down Accelerated Approval Request for T-DM1
- Expert Panel Votes Against Continuing Approval for Avastin to Treat Metastatic Breast Cancer
- Avastin Doesn’t Improve Survival in Metastatic Breast Cancer
- HER2-Positive Breast Cancer May Respond to Experimental Treatments
- Olaparib May Help Treat Triple-Negative Breast Cancer
- Afinitor May Make Metastatic Breast Cancer Start Responding to Other Medicines Again
- Adding Avastin to Chemo Stops Metastatic Cancer From Growing
- Experimental Combo Shows Promise for Treating Metastatic HER2-Positive Cancer
- Retesting Metastatic Cancer’s HER2 Status Can Predict Response to Experimental Medicine
- Avastin Slows Growth of Metastatic Breast Cancer
- Experimental Treatment for HER2-Positive Cancers Shows Promise
- Experimental Regimen May Work Against Treatment-Resistant Breast Cancer
- Radioactive Tag on Herceptin May Allow Doctors to Track Effectiveness
- Avastin-Abraxane Combo May Treat Triple-Negative Breast Cancer
- Herceptin May Destroy Cancer Stem Cells
- Too Much MicroRNA Linked to Herceptin Resistance
- Tykerb May Treat Herceptin-Resistant HER2-Positive Breast Cancer
- HER2 Levels Drop If HER2-Positive Cancers Respond to Chemo Plus Herceptin Before Surgery
- Avastin Helps Stop Growth of Metastatic Breast Cancer
- FDA Approves Tykerb-Femara Combo to Treat Advanced-Stage Disease
- Herceptin Plus Chemo Before Surgery Better Than Chemo Alone for HER2-Positive Locally-Advanced Disease
- Experimental Combo of Herceptin and Maytansine May Help Treat Metastatic HER2-Positive Breast Cancer
- Avastin Doesn’t Affect Overall Survival in Metastatic Breast Cancer
- Herceptin Plus Tykerb Improves Survival for Women with Metastatic HER2-Positive Breast Cancer
- New Targeted Therapies Studied
- Timing of Herceptin Influences Risk of Recurrence
- Targeting Breast Cancer Stem Cells May Help Lower Recurrence Risk
- Denosumab Slightly Better Than Zometa at Easing Bone Pain, Complications of Metastatic Breast Cancer
- Experimental Targeted Therapy Makes Chemotherapy Work Better
- HER2 Boosts Recurrence Risk Even for Small Breast Cancers
- Herceptin Helps Treat Early-Stage, HER2-Positive Cancers
- Experimental Olaparib May Help Treat People with Abnormal BRCA1 or BRCA2 Gene
- Some Estrogen-Receptor-Negative Breast Cancers Become Estrogen-Receptor-Positive After Herceptin Treatment
- New Type of Targeted Therapy May Help Treat Triple-Negative Disease
- Tykerb May Help Treat HER2-Positive Inflammatory Breast Cancer
- New Therapies Vie for Role in Breast Cancer
- Herceptin Before Surgery Offers Benefits
- Avastin Ups Blood Clot Risk
- Experimental HER2 Vaccine Shows Promise
- If Cancer Stops Responding to Herceptin, It May Have Switched from HER2-Positive to HER2-Negative
- Scientists Discover Compound That Blocks Breast Cancer Growth Signals
- Adding Tykerb to Herceptin Helps if Metastatic Breast Cancer Grows
- Avastin Seems to Offer Benefits in Treating Metastatic Breast Cancer
- Experimental Vaccine May Help Treat HER2-Positive Cancers
- Herceptin with Dose-Dense Chemo Reduces Risk of Heart Problems
- New Study Compares Tykerb and Herceptin
- Avastin Approved to Treat Breast Cancer
- Avastin Doesn’t Affect Overall Survival
- Tykerb and Xeloda Effective on Breast Cancer in Brain
- Experts Say No to Avastin for Breast Cancer
- 2007-09-26: Inflammatory HER2-Positive Breast Cancer Responds to Herceptin
- Herceptin Approved in Europe to Treat Breast Cancer
- Herceptin-Avastin Combo Shows Promise
- FDA Approves Herceptin to Treat Early-Stage Disease
- Herceptin Plus Arimidex Can Help Treat Advanced-Stage Breast Cancer
- Taxotere and Herceptin Reduces Recurrence of Early-Stage Breast Cancer
